Evidence map›Paper›PMID 38983404›Full record

ArticleWorld journal of clinical cases2024

Exploring the potential mechanism of WuFuYin against hypertrophic scar using network pharmacology and molecular docking.

Shu-Yang Zhang, Song-Xue Guo, Lei-Lei Chen, Jia-Yan Zhu, Ming-Sheng Hou, Jia-Ke Lu, Xue-Xiang Shen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shu-Yang ZhangDepartment of General Surgery, Shaoxing Hospital of Traditional Chinese Medicine, Shaoxing 312000, Zhejiang Province, China.
Song-Xue GuoDepartment of Plastic Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, China.
Lei-Lei ChenHand and Plastic Surgery, The first People's Hospital of Linping District, Hangzhou 311013, Zhejiang Province, China.
Jia-Yan ZhuDepartment of General Surgery, Shaoxing Hospital of Traditional Chinese Medicine, Shaoxing 312000, Zhejiang Province, China.
Ming-Sheng HouDepartment of Pathology, Shaoxing Hospital of Traditional Chinese Medicine, Shaoxing 312000, Zhejiang Province, China.
Jia-Ke LuDepartment of Traumatology, Yuyao Hospital of Traditional Chinese Medicine, Ningbo 315400, Zhejiang Province, China.
Xue-Xiang ShenDepartment of General Surgery, Shaoxing Hospital of Traditional Chinese Medicine, Shaoxing 312000, Zhejiang Province, China. zsyzsy0522@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypertrophic scar (HTS) is dermal fibroproliferative disorder, which may cause physiological and psychological problems. Currently, the potential mechanism of WuFuYin (WFY) in the treatment of HTS remained to be elucidated.

aimTo explore the potential mechanism of WFY in treating HTS.

methodsActive components and corresponding targets were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. HTS-related genes were obtained from the GeneCards, DisGeNET, and National Center for Biotechnology Information. The function of targets was analyzed by performing Gene Ontology and Kyoto Encyclopaedia of Genes and Genome (KEGG) enrichment analysis. A protein + IBM-protein interaction (PPI) network was developed using STRING database and Cytoscape. To confirm the high affinity between compounds and targets, molecular docking was performed.

resultsA total of 65 core genes, which were both related to compounds and HTS, were selected from multiple databases. PPI analysis showed that

conclusionThe current findings showed that the

Indexed as

Enrichment analysisHypertrophic scarMolecular dockingNetwork pharmacologyWuFuYin

Identifiers

PMID38983404
PMCPMC11229930

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.